Cloverfields Capital Group LP lifted its holdings in UnitedHealth Group Incorporated (NYSE:UNH) by 0.1% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 621,417 shares of the healthcare conglomerate’s stock after buying an additional 682 shares during the quarter. UnitedHealth Group makes up about 72.2% of Cloverfields Capital Group LP’s portfolio, making the stock its biggest position. Cloverfields Capital Group LP owned 0.07% of UnitedHealth Group worth $248,840,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also modified their holdings of the company. First Manhattan Co. raised its holdings in shares of UnitedHealth Group by 19.7% in the first quarter. First Manhattan Co. now owns 1,482,677 shares of the healthcare conglomerate’s stock worth $551,661,000 after buying an additional 243,529 shares during the period. GWM Advisors LLC increased its holdings in UnitedHealth Group by 8.3% during the 2nd quarter. GWM Advisors LLC now owns 31,240 shares of the healthcare conglomerate’s stock worth $12,510,000 after purchasing an additional 2,397 shares during the period. Veritas Asset Management LLP increased its holdings in UnitedHealth Group by 0.4% during the 1st quarter. Veritas Asset Management LLP now owns 2,572,968 shares of the healthcare conglomerate’s stock worth $957,324,000 after purchasing an additional 10,713 shares during the period. Seven Springs Wealth Group LLC increased its holdings in UnitedHealth Group by 58.6% during the 2nd quarter. Seven Springs Wealth Group LLC now owns 2,544 shares of the healthcare conglomerate’s stock worth $1,019,000 after purchasing an additional 940 shares during the period. Finally, Reliant Investment Management LLC increased its holdings in UnitedHealth Group by 2.0% during the 1st quarter. Reliant Investment Management LLC now owns 13,324 shares of the healthcare conglomerate’s stock worth $4,957,000 after purchasing an additional 255 shares during the period. Hedge funds and other institutional investors own 86.21% of the company’s stock.
In related news, CEO Andrew Witty sold 6,000 shares of UnitedHealth Group stock in a transaction dated Wednesday, July 21st. The stock was sold at an average price of $414.15, for a total value of $2,484,900.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO John F. Rex sold 15,438 shares of UnitedHealth Group stock in a transaction dated Thursday, July 29th. The shares were sold at an average price of $412.04, for a total value of $6,361,073.52. The disclosure for this sale can be found here. In the last three months, insiders sold 101,438 shares of company stock valued at $42,396,929. Insiders own 0.55% of the company’s stock.
UnitedHealth Group (NYSE:UNH) last issued its quarterly earnings results on Wednesday, July 14th. The healthcare conglomerate reported $4.70 EPS for the quarter, topping the Zacks’ consensus estimate of $4.43 by $0.27. The company had revenue of $71.32 billion during the quarter, compared to analysts’ expectations of $69.51 billion. UnitedHealth Group had a return on equity of 22.15% and a net margin of 5.33%. The firm’s revenue was up 14.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $7.12 EPS. Analysts predict that UnitedHealth Group Incorporated will post 18.74 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 21st. Stockholders of record on Monday, September 13th were issued a $1.45 dividend. The ex-dividend date of this dividend was Friday, September 10th. This represents a $5.80 annualized dividend and a dividend yield of 1.42%. UnitedHealth Group’s dividend payout ratio (DPR) is presently 34.36%.
Several research firms have commented on UNH. Raymond James raised their price objective on UnitedHealth Group from $435.00 to $515.00 and gave the stock a “strong-buy” rating in a report on Friday, July 16th. Morgan Stanley cut their price target on UnitedHealth Group from $515.00 to $488.00 and set an “overweight” rating on the stock in a report on Tuesday, August 31st. Oppenheimer reiterated a “buy” rating and issued a $440.00 price target on shares of UnitedHealth Group in a report on Thursday, July 15th. Cowen started coverage on UnitedHealth Group in a report on Thursday, September 9th. They issued an “outperform” rating and a $478.00 price target on the stock. Finally, Citigroup lifted their price target on UnitedHealth Group from $450.00 to $480.00 and gave the company a “buy” rating in a report on Friday, July 16th. Three equities research analysts have rated the stock with a hold rating, twenty have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, UnitedHealth Group has a consensus rating of “Buy” and an average target price of $447.79.
UnitedHealth Group Profile
UnitedHealth Group, Inc engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum’s capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience.
Receive News & Ratings for UnitedHealth Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UnitedHealth Group and related companies with MarketBeat.com's FREE daily email newsletter.